Mounjaro KwikPen 7.5mg: what changes at this stage of treatment

Picture the moment your prescriber says you're ready to move up

You've been on the 5mg KwikPen for four weeks, the nausea that arrived in week one has largely quietened, and your appetite has shifted, meals feel smaller, snacking has reduced. The question of what comes next is a reasonable one. At 7.5mg, tirzepatide's dual action on GIP and GLP-1 receptors intensifies: gastric emptying slows a little further, satiety signals stay elevated for longer, and for many people the sense of reduced hunger becomes more consistent across the whole week rather than tapering off before the next injection.

Clinically, 7.5mg sits in the middle of the licensed schedule. It is neither a starter dose nor a maintenance ceiling. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants on tirzepatide across the programme saw average weight reductions that grew with each successive dose, so reaching 7.5mg is a genuine step in that trajectory, not a pause. Your prescriber will want to know how your body responded at 5mg before confirming the move. That conversation matters.

One practical note: store the new pen in the fridge door as soon as it arrives, it is the coolest, most consistent spot in most household fridges, and keeping your pen somewhere visible makes it easier to remember your weekly injection without disrupting your routine.

The side effects most likely to return when you step up to 7.5mg

A dose increase is, in effect, a new exposure. The gastrointestinal profile of tirzepatide (nausea, loose stools, constipation, indigestion, a feeling of fullness that can tip into discomfort) tends to be most noticeable when you first start a higher strength. Most people find these effects are milder the second or third time around than they were when starting the 2.5mg pen, which is where tirzepatide treatment begins for most people, because the body has built some tolerance. But they can still catch people off guard. The NHS tirzepatide medicines page sets out the full common-side-effect list and the symptoms that warrant urgent medical attention, and it is worth revisiting it at each step up.

Serious but uncommon effects to stay alert to include severe, persistent stomach pain that reaches through to the back (a possible sign of pancreatitis) and gallbladder symptoms. Neither of these is common; both need prompt medical assessment if they occur. Injection-site reactions, headache and fatigue are also listed. The general guidance at any dose: eat smaller portions, stay well hydrated, and avoid rich or fatty meals in the days after your injection. Your prescriber and the patient information leaflet that comes with your pen are the right sources for how to manage specific symptoms.

If you are unsure whether a symptom is dose-adjustment-related or something that needs medical review, contact a clinician. Waiting it out without checking is rarely the right call at a new dose.

Who reaches 7.5mg, and what the prescriber is weighing up

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition such as high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes. Ethnic-background adjustments to those BMI thresholds apply under UK guidance. Reaching 7.5mg specifically requires that your prescriber is satisfied you have tolerated the 5mg pen adequately, it is not automatic at the four-week mark if your response suggests a longer period at 5mg would be safer or more appropriate.

NICE's appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing treatment is reviewed. That review is relevant context for anyone approaching the mid-range doses: the goal of titration is to find the dose that delivers meaningful benefit with manageable side effects, which is not always the highest available strength. Some people remain at 7.5mg long-term; others move on to 10mg after a further four weeks. The right answer depends on your individual clinical picture, not a generalised schedule.

If you are considering whether tirzepatide at any dose is appropriate for you, a good starting point is the Mounjaro overview page, which covers the full licensed schedule and eligibility criteria. Those who want to understand how the earlier dose compares can also read about how strong 5mg tirzepatide is in clinical terms.

Getting a 7.5mg KwikPen through a regulated online pharmacy

The only legal route to any strength of tirzepatide in the UK is a prescription, issued by a qualified prescriber following a proper clinical assessment. Online pharmacies registered with the GPhC and regulated by the MHRA can legally dispense it, you can verify any online pharmacy at the GPhC register before handing over any personal or payment information.

At nume, every request for a repeat pen (including a step up to 7.5mg) is reviewed by a GPhC-registered Independent Prescriber, a real clinician reading your case, before anything is dispatched. There is no algorithm making that call. If you are already in treatment and thinking about what the next dose involves, our FAQs page covers common questions about moving between strengths. For a broader look at the weight-loss treatment options available through a regulated UK service, that page sets out the full picture. When you are ready to talk to a prescriber about your own eligibility, you can check your eligibility and start a free consultation, there is no obligation, and the clinical review happens the same day.